OTLK Outlook Therapeutics Inc

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Outlook Therapeutics (OTLK – Research Report), Denali Therapeutics (DNLI – Research Report) and Mereo Biopharma Group Plc (MREO – Research Report) with bullish sentiments. Outlook Therapeutics (OTLK) Outlook Therapeutics received a Buy rating and a $7.00 price target from BTIG analyst Julian Harrison on October 31. The company's shares closed last Tuesday at $1.15. According to TipRanks.
https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-204?utm_source=advfn.com&utm_medium=referral